Big-money investors, aka “whales,” have taken a cautiously bearish turn on Airbnb’s options, making more put trades than ...

Zacks Research has upped the financial bar for Vertex Pharmaceuticals, boosting its 2026 earnings forecast from $16.18 to $16 ...

Bank of Nova Scotia made a sharp U-turn, slashing its Deere & Company holdings by a whopping 58.2% in Q4. This dramatic trim ...

Bessemer Group Inc. just spilled most of its Starbucks stock—selling a piping hot 91.1% of its stake in the fourth quarter.

Christopher D’Ambrosio, a corporate VP at ADP, sold 478 shares for $140,120 while the stock hovered near a 52-week high. This ...

Analysts are playing financial ping-pong with The Cigna Group’s price target, but the net effect is positive. Truist ...

Legacy Financial Advisors trimmed its Lockheed Martin stake by nearly 38% last quarter, offloading 1,048 shares and leaving ...

Analysts can't seem to agree on Marsh & McLennan's stock direction, but one thing's clear—it’s making headlines. Keefe, ...

UBS Group slashed Bristol-Myers Squibb’s price target from $60 to $54, keeping its rating at a neutral "meh." Other analysts ...

Cerity Partners gave Regeneron a small but mighty vote of confidence, upping their stake by 3.3% in the fourth quarter. They ...

Wellington Management Group shaved off a tiny sliver of its CVS Health stake, reducing it by 1.8% during Q4. The firm still ...

Truist Financial trimmed its price target from $120 to $113, but kept the "buy" label firmly in place. This move follows a ...